Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It is grouped under the following drug class(es): DPP-4 inhibitors. Its therapeutic use is listed as antidiabetic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include MK-3102, omarigliptinum, (2H-Pyran-3-amine, 2-(2, 5-difluorophenyl)-5-(2, 6-dihydro-2-(methylsulfonyl)pyrrolo(3, 4-c)pyrazol-5(4H)-yl)tetrahydro-, (2R, 3S and 5R)-). Its PubChem CID is 46209133.
Omarigliptin
| CAS No | 1226781-44-7 |
|---|---|
| Molecular Formula | C17H20F2N4O3S |
| Molecular Weight | 398.4 g/mol |
| Synonyms | (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co.
The listed CAS number is 1226781-44-7.
The listed molecular formula is C17H20F2N4O3S.
The listed molecular weight is 398.4 g/mol.
(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine.
The source lists MK-3102, omarigliptinum, (2H-Pyran-3-amine, 2-(2, 5-difluorophenyl)-5-(2, 6-dihydro-2-(methylsulfonyl)pyrrolo(3, 4-c)pyrazol-5(4H)-yl)tetrahydro-, (2R, 3S and 5R)-).